NDAOPHTHALMICSOLUTION
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
CEQUA (cyclosporine) by Fosun Pharma is calcineurin inhibitors [moa]. Approved for dry eye disease, kidney transplantation, liver transplantation. First approved in 2018.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEQUA is a calcineurin inhibitor immunosuppressant delivered as an ophthalmic solution containing cyclosporine. Approved by the FDA in August 2018, it is indicated for the treatment of dry eye disease by reducing inflammation and suppressing immune-mediated tear gland dysfunction. The drug works by inhibiting calcineurin-dependent T-cell activation, thereby modulating the immune response in the ocular surface. CEQUA represents a branded formulation strategy in a market historically dominated by the original cyclosporine product RESTASIS.
$0.1BPart D
10.8 years to LOEMechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications (3)
Worked on CEQUA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.